$24,750.00 | '
Angelman’s Syndrome | Executive Insights | US/EU5/China | 2021
Clarivate publishes content on Angelman syndrome and its current and future management, patient journey, and the competitive landscape in the U.S., EU5, and China markets between 2021 and 2031
Related Market Assessment Reports
Report
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (US)
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAAD) is a rare autoimmune inflammatory CNS disorder defined by IgG antibodies targeting the myelin oligodendrocyte glycoprotein…
Report
Painful Diabetic Neuropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Painful Diabetic Neuropathy (US)
Painful diabetic neuropathy (PDN) is a prevalent complication of diabetes, typically causing persistent burning, tingling, or sharp pain in the extremities. Management relies on a range of…
Report
Bipolar Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Bipolar Disorder (US)
Bipolar disorder (BPD) is a chronic condition characterized by recurrent episodes of aberrant mood, with patients experiencing manic, depressive, or mixed symptoms between periods of stable mood…
Report
Rheumatoid Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Rheumatoid Arthritis (US)
The treatment of rheumatoid arthritis (RA) typically begins with cost-effective conventional DMARDs (cDMARDs) such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or…
